Abbott Laboratories (NYSE:ABT) insider Alejandro D. Wellisch sold 2,153 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the completion of the sale, the insider now owns 10,256 shares in the company, valued at $572,900.16. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Abbott Laboratories (NYSE:ABT) traded down $0.32 during mid-day trading on Wednesday, reaching $55.80. 3,552,077 shares of the company’s stock traded hands, compared to its average volume of 6,639,404. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The company has a market capitalization of $97,130.00, a P/E ratio of 22.94, a price-to-earnings-growth ratio of 2.07 and a beta of 1.55. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $56.69.
Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The company had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.59 earnings per share. sell-side analysts expect that Abbott Laboratories will post 2.49 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Alejandro D. Wellisch Sells 2,153 Shares of Abbott Laboratories (ABT) Stock” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/22/alejandro-d-wellisch-sells-2153-shares-of-abbott-laboratories-abt-stock.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Sanders Morris Harris LLC boosted its holdings in shares of Abbott Laboratories by 0.3% during the 2nd quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock worth $242,000 after buying an additional 16 shares during the period. St. Louis Trust Co boosted its holdings in shares of Abbott Laboratories by 0.4% during the 2nd quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock worth $238,000 after buying an additional 20 shares during the period. Alpha Windward LLC boosted its holdings in shares of Abbott Laboratories by 0.6% during the 2nd quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker’s stock worth $264,000 after buying an additional 30 shares during the period. Lakeview Capital Partners LLC boosted its holdings in shares of Abbott Laboratories by 0.6% during the 2nd quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock worth $277,000 after buying an additional 33 shares during the period. Finally, Johanson Financial Advisors Inc. boosted its holdings in Abbott Laboratories by 0.5% in the 2nd quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock valued at $343,000 after purchasing an additional 37 shares during the period. 69.99% of the stock is owned by institutional investors and hedge funds.
ABT has been the topic of a number of research reports. Cowen and Company reiterated a “buy” rating on shares of Abbott Laboratories in a report on Sunday, September 24th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a report on Friday, September 22nd. Jefferies Group LLC reiterated a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a report on Thursday, August 3rd. BidaskClub downgraded shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Royal Bank Of Canada restated a “buy” rating and set a $55.00 price target on shares of Abbott Laboratories in a report on Tuesday, October 3rd. Seven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $56.81.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.